Skip to main content
eScholarship
Open Access Publications from the University of California

Characteristics Associated with Inter-Individual Differences in the Trajectories of Self-Reported Attentional Function in Oncology Outpatients Receiving Chemotherapy

  • Author(s): Shih, Juliet
  • Advisor(s): Miaskowski, Christine
  • et al.
Abstract

Between 14% and 85% of patients report noticeable changes in cognitive function during chemotherapy (CTX). These cognitive changes include alterations in memory, psychomotor speed, and executive functioning. Executive function encompasses a person’s ability to direct attention towards planning, decision-making, and abstract thinking. The purposes of this study were to determine which demographic, clinical, and symptom characteristics were associated with inter-individual variability in initial levels of attentional function as well as with changes in the trajectories of attentional function in a sample of oncology patients who underwent two cycles of CTX. Oncology outpatients were recruited from two Comprehensive Cancer Centers, one Veteran’s Affairs hospital, and four community-based oncology programs. The Attentional Function Index (AFI) was used to assess perceived effectiveness in completing daily tasks that required working memory and attention. Hierarchical linear modeling (HLM) was used to evaluate inter-individual variability in initial levels and the trajectories of attentional function. Patients were receiving CTX for breast, gastrointestinal, gynecological, or lung cancer (n = 1,329). The demographic, clinical, and symptom characteristics that were associated with inter-individual differences of attentional function at enrollment (i.e., intercept) were: employment status, functional status, trait anxiety, depressive symptoms, sleep disturbance, evening fatigue, and morning energy. Gender was the only characteristic associated with inter-individual differences in the trajectories of attentional function. Morning fatigue was the only characteristic associated with both initial levels as well as the trajectories of attentional function. On average, prior to the next dose of CTX, patients reported moderate levels of attentional function that persisted over two cycles of CTX. Many of the clinical and symptom characteristics are amenable to interventions. Clinicians need to assess patients for changes in attentional function and associated characteristics and recommend evidence-based interventions.

Main Content
Current View